Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCRIT in Elective Major Abdominal or Pelvic Surgery
NCT00350519Phase 4
Key facts
- Status
- Terminated
- Start
- Aug 2006
- Primary completion
- Feb 2008
- Sponsor
- Johnson & Johnson
- Modality
- Biologic, rProtein (Recombinant Protein)
- Drugs
- epoetin alfa
- Conditions
- anemia
01
Overview
Phase 4, randomised, open-label trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Primary endpoint: Number of Participants Receiving Packed Red Blood Cell Transfusions. Started Aug 2006; status: terminated.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients scheduled for elective major abdominal or pelvic surgery with anticipated significant blood loss and hemoglobin levels between 10 and 13 g/dL.
04
Endpoints
Primary
Number of Participants Receiving Packed Red Blood Cell Transfusions
Beyond the preview
Go deeper on NCT00350519.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00350519.